Abstracts Archive - Page 747 of 2425 - ACR Meeting Abstracts

Abstract Number: 1385 • ACR Convergence 2020
Physical Therapy in Patients with Systemic Sclerosis: The Perspective of Physical Therapists on Current Delivery and Educational Needs
Sophie Liem¹, Nina van Leeuwen², Thea Vliet Vlieland³, Lian de Pundert⁴, Rita Schriemer⁵, Julia Spierings⁶, Madelon Vonk⁷ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, 2300 RC Leiden, Netherlands, ⁴HAGA Hospital, The Hague, Netherlands, ⁵NVLE, Utrecht, ⁶University Medical Center Utrecht, Maastricht, Netherlands, ⁷Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands
Background/Purpose: As there is currently no cure available for systemic sclerosis (SSc), nonpharmacologic care is an essential element in the management of the disease. Physical…
Abstract Number: 1386 • ACR Convergence 2020
Clinical Correlates and Relevance of the UCLA GIT 2.0 Instrument for Indication for Esophagogastroduodenoscopy and Endoscopic Esophagitis in Real-life Patients with Systemic Sclerosis
Norina Zampatti¹, Alexandru Garaiman¹, Suzana Jordan¹, Britta Maurer², Rucsandra Dobrota¹, Mike Oliver Becker¹, Oliver Distler³ and Carina Mihai¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Gastrointestinal (GI) tract involvement is the most common of all internal organ involvement in systemic sclerosis (SSc). The University of California at Los Angeles,…
Abstract Number: 1387 • ACR Convergence 2020
Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?
Megan Meier¹, Jacob Stever², Josephine Wright¹, Tracy Frech³, Greg Stoddard¹ and Benjamin Tingey¹, ¹University of Utah, Salt Lake City, ²University of Utah, SANDY, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Scleroderma renal crisis (SRC) is a well-characterized condition in patients with systemic sclerosis, but systemic sclerosis patients frequently develop chronic kidney disease (CKD) without…
Abstract Number: 1388 • ACR Convergence 2020
A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Elizabeth Volkmann³, Laura Hummers⁴, Fredrick Wigley⁵ and Zsuzsanna McMahan⁶, ¹JHUSOM, Baltimore, ²JHUSPH, Baltimore, ³University of California, Los Angeles, Los Angeles, CA, ⁴Johns Hopkins Univerisity, Ellicott City, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University, Baltimore
Background/Purpose: Colonic dysmotility affects up to 50% of patients with systemic sclerosis (SSc). While some patients have mild colonic disease, others experience severe complications, such…
Abstract Number: 1389 • ACR Convergence 2020
Clinical Characteristics and Treatment Outcome of a Cohort of Patients with Joint and Fascial Involvement in the Context of Chronic Graft versus Host Disease
Cristina Hidalgo Calleja¹, Concepción Román Curto², Luis Gómez-Lechón³, Maria Elisa Acosta², Olga Compán⁴, Sonia Pastor², Carlos Montilla Morales², Lucía Pantoja Zarza⁵, María Dolores Sánchez González⁶ and Lucía López Corral², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Francesc de Borga de Gandía, Valencia, Spain, ⁴Hospital Universitario de Salamanca, ´Salamanca, Spain, ⁵Complejo Asistencial Hospital General de Segovia, Segovia, Spain, ⁶Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Background/Purpose: Chronic graft-vs-host disease (cGVHD) is a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT), typically occurring within three years post-transplant and affecting…
Abstract Number: 1390 • ACR Convergence 2020
Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample
Atefeh Vafa¹, Omid Behnamfar² and Yih Chang Lin³, ¹University of South Florida, Tampa, FL, ²University of California San Diego, La Jolla, CA, ³University of South Florida, Morsani College of Medicine, Tampa, FL
Background/Purpose: Several systemic autoimmune rheumatic diseases have been shown to increase coronary artery disease (CAD) risk, notable rheumatoid arthritis and systemic lupus erythematosus. However, data…
Abstract Number: 1391 • ACR Convergence 2020
Associations Between Autoantibodies in Systemic Sclerosis and Cancer in a National Registry
Selma Lazizi¹, Marie Hudson², Murray Baron³, Marvin Fritzler⁴ and Sabrina Hoa⁵, ¹Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Jewish General Hospital, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada
Background/Purpose: Autoantibodies are useful in systemic sclerosis (SSc) for predicting disease course. Some autoantibodies have been associated with a close temporal relationship with cancer. We…
Abstract Number: 1392 • ACR Convergence 2020
Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Alberto Sulli¹, Sabrina Paolino¹, Giorgia Ferrari¹, Carmen Pizzorni¹, Elvis Hysa¹, Maurizio Cutolo¹ and Emanuele Gotelli¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy
Background/Purpose: Aminaphtone has been used for many years to treat microvascular disorders. In vitro Aminaphtone counteracts vasoconstriction downregulating endothelin-1 production and interferes with adhesion molecules…
Abstract Number: 1393 • ACR Convergence 2020
Systemic Sclerosis: Subclinical Aterosclerosis and Morbimortality
Miriam Retuerto¹, Jose Luis Rosales², Maria Martin¹, Beatriz Joven¹ and Patricia E Carreira¹, ¹Hospital universitario 12 de octubre, Madrid, Spain, ²Hospiten Rambla, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatic diseases are associated with accelerated atherosclerosis, and an increase in cardiovascular morbidity and mortality. This process is mediated by classic cardiovascular risk factors…
Abstract Number: 1394 • ACR Convergence 2020
Pathway to Systemic Sclerosis: Concerning Patients’ Experiences During the Diagnostic Process
Fennell Patricia¹, Lee Shapiro², Nancy Dorr³, Roberta Lukasiewicz⁴, Frank Houser⁵ and Madison Taylor⁶, ¹Albany Health Management Associates, Steffens Scleroderma Foundation, Albany, NY, ²Albany Medical College, Stillwater, NY, ³The College of Saint Rose, Albany, NY, ⁴Steffens Scleroderma Foundation, Albany, NY, ⁵The College of Saint Rose, Nassau, NY, ⁶The College of Saint Rose, Mississauga, ON, Canada
Background/Purpose: Receiving a diagnosis of systemic sclerosis (SSc) can be straightforward process for some, whereas others have a circuitous route. Given that complications can often…
Abstract Number: 1395 • ACR Convergence 2020
Poor Maternal and Fetal Outcome in Indian Women with Systemic Sclerosis: Interview-based Study at a Tertiary Center in India
Rajat Kharbanda¹, Naveen R², Durga P Misra², Latika Gupta³ and Vikas Agarwal⁴, ¹SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Post Graduate Institute of Medical Sciences, LUCKNOW, India
Background/Purpose: Poor obstetric outcomes have been described in Systemic sclerosis (SSc) in the developed world. We assessed effect of the disease in Indian women and…
Abstract Number: 1396 • ACR Convergence 2020
Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis
Klodian Gjeloshi¹, Giovanni Lettieri², Fiammetta Danzo¹, Giuseppina Abignano³, Mark Hinton⁴, Anne-Maree Dean⁵, Giovanna Cuomo⁶, Olga Kubassova⁷ and Francesco Del Galdo⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK and Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Leeds, United Kingdom, ²Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, ³Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, England, United Kingdom, ⁴IAG CEO, London, United Kingdom, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ⁶Internal Medicine Department, University of Campania Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁷Image Analysis Group, London, United Kingdom
Background/Purpose: Neointima proliferation is a key pathologic feature of Systemic Sclerosis (SSc), causing arterial vessel narrowing. It is a recognised culprit pathological lesion in Digital…
Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Smriti Prasad¹, Samantha Black², Shivani Sharma³ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²The University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern, Dallas, TX
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
Abstract Number: 1398 • ACR Convergence 2020
The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort
Sabrina Elliott¹, Duncan Moore² and Virginia Steen², ¹MedStar Georgetown Hospital, Alexandria, VA, ²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Systemic Sclerosis (SSc) patients with an isolated nucleolar patterned ANA (NUC ANA) make up about 15% of the SSc population, although the specific nucleolar…
Abstract Number: 1399 • ACR Convergence 2020
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Ching-Huang Ho¹, Andrea Silva¹ and I-Cheng Ho², ¹Brigham and Women's Hospital, Boston, MA, ²Birgham and Women's Hospital, Boston, MA
Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].